although
acut
kidney
injuri
aki
frequent
complic
patient
receiv
extracorpor
membran
oxygen
ecmo
studi
conduct
risk
factor
aki
perform
studi
identifi
risk
factor
aki
associ
inhospit
mortal
data
adult
patient
receiv
ecmo
analyz
aki
stage
defin
accord
kidney
diseas
improv
global
outcom
kdigo
classif
variabl
within
h
ecmo
insert
collect
analyz
associ
aki
inhospit
mortal
stage
aki
associ
inhospit
mortal
hazard
ratio
hr
ci
compar
nonaki
p
simplifi
acut
physiolog
score
serum
sodium
level
also
associ
inhospit
mortal
hr
per
score
increas
p
per
mmoll
increas
p
initi
pump
speed
ecmo
significantli
relat
inhospit
mortal
hr
per
rpm
increas
p
pump
speed
also
associ
aki
p
stage
aki
p
or
ci
respect
also
found
red
cell
distribut
width
rdw
significantli
relat
stage
aki
initi
pump
speed
ecmo
signific
risk
factor
inhospit
mortal
aki
patient
receiv
ecmo
rdw
risk
factor
stage
aki
receiv
continu
renal
replac
therapi
ecmo
initi
n
initi
continu
renal
replac
therapi
date
ecmo
insert
n
therefor
patient
ultim
analyz
present
studi
physiolog
laboratori
data
within
h
ecmo
initi
collect
retrospect
review
electron
medic
record
clinic
paramet
record
includ
follow
age
sex
caus
admiss
caus
ecmo
support
mode
ecmo
whether
perform
cardiopulmonari
resuscit
within
h
use
intraaort
balloon
pump
iabp
ecmo
set
durat
ecmo
urin
output
ventil
set
initi
blood
find
includ
blood
urea
nitrogen
bun
total
bilirubin
albumin
white
blood
cell
hemoglobin
level
platelet
number
red
cell
distribut
width
rdw
sodium
potassium
chlorid
creactiv
protein
crp
measur
sever
index
use
simplifi
acut
physiolog
score
calcul
worst
valu
first
h
ecmo
initi
use
aki
stage
sever
defin
accord
guidelin
propos
kdigo
aki
defin
case
either
increas
serum
creatinin
time
baselin
within
h
chang
serum
creatinin
accord
aki
stage
follow
stage
increas
equal
increas
equal
baselin
stage
increas
baselin
stage
increas
baselin
equal
acut
increas
least
l
renal
replac
therapi
maximum
aki
stage
reach
ecmo
support
use
defin
incid
aki
inhospit
mortal
determin
whether
death
certif
issu
ecmo
insert
appli
ecmo
consol
compos
centrifug
pump
membran
oxygen
product
util
includ
capiox
eb
terumo
corpor
tokyo
japan
quadrox
pl
maquet
hirrlingen
germani
valu
express
mean
standard
deviat
continu
variabl
n
categor
variabl
sever
skew
variabl
followup
durat
median
interquartil
rang
iqr
use
differ
analyz
independ
ttest
continu
variabl
chisquar
test
categor
variabl
estim
surviv
kaplanmei
method
employ
statist
signific
calcul
use
logrank
test
multivari
analysi
logist
regress
analysi
aki
coxproport
hazard
analysi
inhospit
mortal
carri
variabl
multivari
analysi
chosen
p
univari
analysi
calibr
done
use
hosmerlemeshow
goodnessoffit
test
compar
number
predict
observ
inhospit
mortal
aki
discrimin
analyz
use
auroc
best
threshold
calcul
obtain
best
youden
index
sensit
consid
p
statist
signific
analys
perform
use
spss
statist
softwar
version
ibm
usa
mean
age
studi
particip
year
particip
male
reason
admiss
cardiovascular
diseas
lung
diseas
malign
other
one
hundr
thirti
seven
patient
receiv
cardiopulmonari
resuscit
within
h
prior
ecmo
initi
median
iqr
day
admiss
patient
receiv
ecmo
insert
cardiotomi
nonop
cardiovascular
caus
adult
respiratori
distress
syndrom
ard
nonard
lung
caus
caus
two
hundr
thirti
patient
receiv
va
vv
ecmo
support
respect
one
hundr
six
patient
undergo
iabp
date
ecmo
insert
median
iqr
durat
ecmo
initi
death
discharg
day
incid
aki
compris
kdigo
grade
inhospit
mortal
median
iqr
durat
aki
inhospit
mortal
day
day
respect
explor
factor
associ
inhospit
mortal
aki
develop
less
frequent
survivor
group
nonsurvivor
group
moreov
stage
aki
develop
significantli
less
survivor
nonsurvivor
serum
sodium
level
significantli
lower
survivor
nonsurvivor
ventil
set
posit
end
expiratori
pressur
peak
inspiratori
pressur
ecmo
insert
affect
surviv
rate
ecmo
pump
speed
significantli
lower
survivor
nonsurvivor
age
caus
admiss
caus
ecmo
support
mode
ecmo
use
iabp
length
stay
ecmo
insert
durat
ecmo
support
initi
urin
output
bun
creatinin
rdw
crp
associ
inhospit
mortal
tabl
perform
multivari
coxproport
hazard
regress
analysi
adjust
confound
effect
among
select
variabl
compar
nonaki
group
stage
aki
group
significantli
increas
risk
inhospit
mortal
wherea
stage
aki
group
tabl
kaplanmei
surviv
curv
accord
stage
aki
estim
mean
ci
surviv
nonaki
group
stage
group
day
day
day
day
respect
p
logrank
test
posthoc
analysi
stage
aki
group
stage
p
p
aki
group
show
signific
differ
surviv
compar
nonaki
group
fig
everi
increment
serum
sodium
level
ecmo
pump
speed
score
mmoll
serum
sodium
level
rpm
ecmo
pump
speed
risk
inhospit
mortal
increas
hr
ci
pvalu
respect
tabl
perform
calibr
discrimin
analysi
serum
sodium
level
ecmo
pump
speed
predict
inhospit
mortal
three
variabl
wellcalibr
auroc
analysi
show
discrimin
power
variabl
cutoff
valu
serum
sodium
level
ecmo
pump
speed
inhospit
mortal
score
mmoll
x
rpm
respect
tabl
compar
clinic
characterist
accord
mode
ecmo
length
hospit
stay
ecmo
insert
shorter
patient
va
mode
vv
mode
level
crp
lower
va
mode
group
vv
mode
group
nonetheless
differ
two
group
initi
ecmo
set
also
compar
two
group
accord
linear
regress
analysi
correl
ecmo
speed
either
vv
mode
r
p
va
mode
r
p
mortal
within
week
ecmo
insert
significantli
higher
patient
va
mode
vv
mode
p
wherea
overal
inhospit
mortal
significantli
lower
va
mode
group
vv
mode
group
p
compar
patient
vv
mode
va
mode
shorter
stay
intens
care
unit
hospit
howev
differ
occurr
aki
two
group
tabl
aki
especi
stage
aki
show
signific
associ
inhospit
mortal
attempt
detect
risk
factor
associ
aki
stage
aki
compar
characterist
patient
without
aki
initi
ecmo
pump
tabl
variabl
also
signific
risk
factor
develop
stage
aki
tabl
addit
risk
factor
stage
aki
rdw
significantli
lower
without
stage
aki
stage
aki
multivari
logist
regress
analysi
rdw
still
statist
signific
ci
pvalu
everi
increas
tabl
calibr
discrimin
analysi
stage
aki
wellcalibr
discrimin
cutoff
valu
rdw
tabl
compar
patient
characterist
accord
rdw
statu
patient
rdw
show
significantli
higher
level
crp
rdw
moreov
patient
rdw
show
consider
lower
hemoglobin
mean
corpuscular
volum
mean
corpuscular
hemoglobin
mean
corpuscular
hemoglobin
concentr
rdw
tabl
work
investig
risk
factor
aki
inhospit
mortal
patient
receiv
ecmo
support
found
initi
pump
speed
ecmo
associ
inhospit
mortal
aki
elev
rdw
could
suggest
risk
factor
sever
aki
patient
first
studi
identifi
risk
factor
aki
adult
patient
receiv
ecmo
support
aki
common
complic
major
risk
factor
mortal
defin
risk
factor
aki
patient
extrem
import
studi
largest
ecmo
assess
ever
report
moreov
associ
pump
speed
aki
mortal
novel
find
show
aki
especi
stage
aki
signific
risk
factor
inhospit
mortal
patient
receiv
ecmo
support
serum
sodium
level
also
import
risk
factor
inhospit
mortal
along
wellknown
expect
find
found
initi
pump
speed
ecmo
significantli
relat
inhospit
mortal
increas
risk
everi
rpm
increas
initi
pump
speed
ecmo
also
risk
factor
aki
stage
aki
hand
blood
flow
rate
ecmo
associ
inhospit
mortal
aki
high
pump
speed
high
blood
flow
rate
ecmo
increas
risk
inhospit
mortal
aki
clear
time
howev
ecmo
pump
induc
hemolysi
leukocyt
platelet
destruct
complement
activ
blood
flow
ecmo
circuit
driven
centrifug
pump
rotat
impel
centrifug
pump
spin
creat
constrain
vortex
suction
blood
pump
propel
toward
membran
oxygen
hemolysi
report
associ
aki
addit
lou
et
al
found
pump
speed
risk
factor
hemolysi
hemolysi
associ
advers
outcom
pediatr
patient
receiv
ecmo
although
evalu
degre
hemolysi
patient
postul
hemolysi
caus
high
revolut
ecmo
pump
might
result
aki
inhospit
mortal
provid
stabl
cardiac
output
va
mode
adequ
oxygen
vv
mode
adequ
blood
flow
maintain
therefor
clinician
rais
ecmo
pump
speed
much
possibl
maintain
adequ
blood
flow
blood
flow
rate
appli
patient
less
lmin
high
blood
flow
extracorpor
circuit
pump
lmin
appli
patient
howev
patient
treat
pump
speed
higher
cutoff
valu
x
rpm
reason
specul
pump
speed
blood
flow
predictor
death
studi
compar
clinic
characterist
patient
va
vv
ecmo
mode
patient
vv
mode
higher
level
crp
show
higher
mortal
longer
stay
hospit
compar
va
mode
howev
mortal
within
week
ecmo
insert
higher
patient
va
mode
specul
patient
va
mode
deterior
rapidli
recov
soon
sever
enough
death
contrast
patient
vv
mode
seem
show
slower
poorer
outcom
va
mode
differ
diseas
process
patient
treat
va
vv
ecmo
mode
might
relat
find
futur
prospect
studi
need
investig
whether
ecmo
mode
determin
outcom
studi
higher
rdw
frequent
stage
aki
occur
best
knowledg
first
studi
suggest
potenti
role
rdw
aki
recent
use
rdw
simpl
inexpens
biomark
predict
mortal
chronic
heart
failur
liver
diseas
critic
ill
increas
moreov
rdw
report
associ
mani
patholog
condit
colon
cancer
inflammatori
bowel
diseas
celiac
diseas
rheumatoid
arthriti
alzheim
diseas
contrastinduc
nephropathi
although
exact
mechan
relationship
clear
inflamm
propos
underli
factor
propos
factor
also
support
data
indic
elev
rdw
associ
high
crp
level
patient
studi
patient
rdw
greater
show
lower
rbc
indic
rdw
less
anemia
risk
factor
aki
low
rbc
indic
found
elev
rdw
group
might
contribut
increas
odd
stage
aki
occur
current
studi
suffer
sever
limit
first
studi
retrospect
cohort
studi
howev
variabl
ecmo
insert
well
retriev
less
miss
rate
moreov
largest
studi
explor
associ
aki
mortal
patient
receiv
ecmo
support
low
level
miss
data
larg
number
patient
could
partial
compens
weak
studi
design
second
classifi
patient
kdigo
stage
base
serum
creatinin
concentr
urin
volum
sensit
marker
earli
detect
aki
patient
ecmo
decreas
urin
volum
ecmo
treatment
andor
day
ecmo
remov
attribut
decreas
cardiac
output
follow
decannul
correl
acut
cardioren
syndrom
type
third
could
provid
direct
evid
hemolysi
due
high
pump
speed
result
aki
studi
measur
plasmafre
hemoglobin
indic
hemolysi
furthermor
obtain
inform
cannul
site
mean
venou
pressur
ecmo
circuit
final
studi
compos
data
two
center
could
limit
generaliz
conclus
aki
signific
risk
factor
inhospit
mortal
patient
receiv
ecmo
support
initi
pump
speed
ecmo
associ
inhospit
mortal
strongli
relat
aki
especi
stage
aki
therefor
adequ
blood
flow
maintain
clinician
must
care
increas
ecmo
pump
speed
elev
rdw
also
strongli
relat
stage
aki
special
attent
paid
patient
abnorm
rdw
valu
prevent
aki
